Novo Nordisk Expands Foothold with Ozempic and Wegovy as Medicare Policies Shift
Sunday, 2 June 2024, 12:25
Discovering Growth Drivers
The success of Ozempic and Wegovy is fueling Novo Nordisk's business growth. Recently, Medicare expanded its coverage to include Wegovy for patients with cardiovascular complications. This move highlights the shift in policies that could have significant implications for Novo Nordisk's future trajectory.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.